Comparison of long-term oncologic outcomes between metastatic ovarian carcinoma originating from gastrointestinal organs and advanced mucinous ovarian carcinoma
Background Occasionally, ovarian tumors are found to have originated from non-ovarian organs as metastatic lesions since the ovary is a common site of metastasis from many cancers. The aim of the current study was to estimate the long-term oncologic outcome of patients with metastatic mucinous ovari...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical oncology 2019-08, Vol.24 (8), p.950-956 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 956 |
|---|---|
| container_issue | 8 |
| container_start_page | 950 |
| container_title | International journal of clinical oncology |
| container_volume | 24 |
| creator | Kajiyama, Hiroaki Suzuki, Shiro Utsumi, Fumi Yoshikawa, Nobuhisa Nishino, Kimihiro Ikeda, Yoshiki Niimi, Kaoru Yamamoto, Eiko Kawai, Michiyasu Shibata, Kiyosumi Nagasaka, Tetsuro Kikkawa, Fumitaka |
| description | Background
Occasionally, ovarian tumors are found to have originated from non-ovarian organs as metastatic lesions since the ovary is a common site of metastasis from many cancers. The aim of the current study was to estimate the long-term oncologic outcome of patients with metastatic mucinous ovarian carcinoma (MmOC) in comparison with those with primary mucinous ovarian carcinoma (PmOC) at an advanced stage.
Materials and methods
The data of one hundred and sixty-seven patients with mucinous ovarian cancer, including 91 patients with MmOC from the digestive organs and 76 patients with stage III–IV PmOC, were retrospectively analyzed. The prognostic significances of clinicopathologic factors were evaluated employing both uni- and multivariable analyses. Pathological slides were evaluated based on centralized pathological review.
Results
The median age of patients with PmOC and MmOC was 55 (18–81) and 51 years (30–82), respectively. With follow-up of a total of 167 patients, 145 patients (86.8%) developed recurrence. In addition, 122 patients (73.0%) died of the disease. Regardless of the residual tumor status, patients with PmOC did not a show a significantly poorer OS than those with MmOC. Furthermore, in a Cox multivariable hazard model, after adjustment for various clinicopathologic confounders, a gastric cancer (GC)-originated tumor and larger residual tumor were significant predictors of poorer OS [GC (vs. PmOC): HR (95% CI) 2.205 (1.303–3.654),
P
= 0.0036].
Conclusion
The oncologic outcome of patients with MmOC was extremely poor; however, it was almost the same as that of those with PmOC. We should recognize MmOC derived from gastric carcinoma as a highly aggressive malignancy. |
| doi_str_mv | 10.1007/s10147-019-01438-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2202682338</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2201956284</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-c310bc0c5d657c722f19e7f767fe21f2ea54cc8d99ab9f26255ec61fe74144393</originalsourceid><addsrcrecordid>eNp9kc2KFTEQhYMozo--gAsJuHHTmr9OOku5jI4w4EbXITddaXroJNeke8S38VGtO3dUUHARUqS-c1LJIeQFZ284Y-Zt44wr0zFucSk5dPoROcfCdMYY8RhrqXhntejPyEVrt4xxo3vxlJxJZhXvpTonP3YlHXydW8m0RLqUPHUr1ERLDmUp0xxo2dZQEjS6h_UbQKYJVt9Wvx57d6j1mQZfw5xL8rTUeZozNvNEYy2JTsjWMucVGh76BYnJ50Z9Hqkf73wOMNK0HeVb-9fwGXkS_dLg-cN-Sb68v_q8u-5uPn34uHt30wWl-NoFydk-sNCPujfBCBG5BRONNhEEjwJ8r0IYRmv93kaBf9JD0DyCUVwpaeUleX3yPdTydcNZXZpbgGXxGXAwJwQTehBSDoi--gu9LVvFp91T3PZaDAopcaJCLa1ViO5Q5-Trd8eZO-bnTvk5VLj7_JxG0csH622fYPwt-RUYAvIENGzlCeqfu_9j-xPVeqon</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2201956284</pqid></control><display><type>article</type><title>Comparison of long-term oncologic outcomes between metastatic ovarian carcinoma originating from gastrointestinal organs and advanced mucinous ovarian carcinoma</title><source>SpringerLink Journals - AutoHoldings</source><creator>Kajiyama, Hiroaki ; Suzuki, Shiro ; Utsumi, Fumi ; Yoshikawa, Nobuhisa ; Nishino, Kimihiro ; Ikeda, Yoshiki ; Niimi, Kaoru ; Yamamoto, Eiko ; Kawai, Michiyasu ; Shibata, Kiyosumi ; Nagasaka, Tetsuro ; Kikkawa, Fumitaka</creator><creatorcontrib>Kajiyama, Hiroaki ; Suzuki, Shiro ; Utsumi, Fumi ; Yoshikawa, Nobuhisa ; Nishino, Kimihiro ; Ikeda, Yoshiki ; Niimi, Kaoru ; Yamamoto, Eiko ; Kawai, Michiyasu ; Shibata, Kiyosumi ; Nagasaka, Tetsuro ; Kikkawa, Fumitaka</creatorcontrib><description>Background
Occasionally, ovarian tumors are found to have originated from non-ovarian organs as metastatic lesions since the ovary is a common site of metastasis from many cancers. The aim of the current study was to estimate the long-term oncologic outcome of patients with metastatic mucinous ovarian carcinoma (MmOC) in comparison with those with primary mucinous ovarian carcinoma (PmOC) at an advanced stage.
Materials and methods
The data of one hundred and sixty-seven patients with mucinous ovarian cancer, including 91 patients with MmOC from the digestive organs and 76 patients with stage III–IV PmOC, were retrospectively analyzed. The prognostic significances of clinicopathologic factors were evaluated employing both uni- and multivariable analyses. Pathological slides were evaluated based on centralized pathological review.
Results
The median age of patients with PmOC and MmOC was 55 (18–81) and 51 years (30–82), respectively. With follow-up of a total of 167 patients, 145 patients (86.8%) developed recurrence. In addition, 122 patients (73.0%) died of the disease. Regardless of the residual tumor status, patients with PmOC did not a show a significantly poorer OS than those with MmOC. Furthermore, in a Cox multivariable hazard model, after adjustment for various clinicopathologic confounders, a gastric cancer (GC)-originated tumor and larger residual tumor were significant predictors of poorer OS [GC (vs. PmOC): HR (95% CI) 2.205 (1.303–3.654),
P
= 0.0036].
Conclusion
The oncologic outcome of patients with MmOC was extremely poor; however, it was almost the same as that of those with PmOC. We should recognize MmOC derived from gastric carcinoma as a highly aggressive malignancy.</description><identifier>ISSN: 1341-9625</identifier><identifier>EISSN: 1437-7772</identifier><identifier>DOI: 10.1007/s10147-019-01438-6</identifier><identifier>PMID: 30941534</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Cancer Research ; Clinical outcomes ; Comparative studies ; Gastric cancer ; Malignancy ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; Oncology ; Original Article ; Ovarian cancer ; Ovarian carcinoma ; Surgical Oncology ; Tumors</subject><ispartof>International journal of clinical oncology, 2019-08, Vol.24 (8), p.950-956</ispartof><rights>Japan Society of Clinical Oncology 2019</rights><rights>International Journal of Clinical Oncology is a copyright of Springer, (2019). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-c310bc0c5d657c722f19e7f767fe21f2ea54cc8d99ab9f26255ec61fe74144393</citedby><cites>FETCH-LOGICAL-c441t-c310bc0c5d657c722f19e7f767fe21f2ea54cc8d99ab9f26255ec61fe74144393</cites><orcidid>0000-0003-0493-1825</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10147-019-01438-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10147-019-01438-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30941534$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kajiyama, Hiroaki</creatorcontrib><creatorcontrib>Suzuki, Shiro</creatorcontrib><creatorcontrib>Utsumi, Fumi</creatorcontrib><creatorcontrib>Yoshikawa, Nobuhisa</creatorcontrib><creatorcontrib>Nishino, Kimihiro</creatorcontrib><creatorcontrib>Ikeda, Yoshiki</creatorcontrib><creatorcontrib>Niimi, Kaoru</creatorcontrib><creatorcontrib>Yamamoto, Eiko</creatorcontrib><creatorcontrib>Kawai, Michiyasu</creatorcontrib><creatorcontrib>Shibata, Kiyosumi</creatorcontrib><creatorcontrib>Nagasaka, Tetsuro</creatorcontrib><creatorcontrib>Kikkawa, Fumitaka</creatorcontrib><title>Comparison of long-term oncologic outcomes between metastatic ovarian carcinoma originating from gastrointestinal organs and advanced mucinous ovarian carcinoma</title><title>International journal of clinical oncology</title><addtitle>Int J Clin Oncol</addtitle><addtitle>Int J Clin Oncol</addtitle><description>Background
Occasionally, ovarian tumors are found to have originated from non-ovarian organs as metastatic lesions since the ovary is a common site of metastasis from many cancers. The aim of the current study was to estimate the long-term oncologic outcome of patients with metastatic mucinous ovarian carcinoma (MmOC) in comparison with those with primary mucinous ovarian carcinoma (PmOC) at an advanced stage.
Materials and methods
The data of one hundred and sixty-seven patients with mucinous ovarian cancer, including 91 patients with MmOC from the digestive organs and 76 patients with stage III–IV PmOC, were retrospectively analyzed. The prognostic significances of clinicopathologic factors were evaluated employing both uni- and multivariable analyses. Pathological slides were evaluated based on centralized pathological review.
Results
The median age of patients with PmOC and MmOC was 55 (18–81) and 51 years (30–82), respectively. With follow-up of a total of 167 patients, 145 patients (86.8%) developed recurrence. In addition, 122 patients (73.0%) died of the disease. Regardless of the residual tumor status, patients with PmOC did not a show a significantly poorer OS than those with MmOC. Furthermore, in a Cox multivariable hazard model, after adjustment for various clinicopathologic confounders, a gastric cancer (GC)-originated tumor and larger residual tumor were significant predictors of poorer OS [GC (vs. PmOC): HR (95% CI) 2.205 (1.303–3.654),
P
= 0.0036].
Conclusion
The oncologic outcome of patients with MmOC was extremely poor; however, it was almost the same as that of those with PmOC. We should recognize MmOC derived from gastric carcinoma as a highly aggressive malignancy.</description><subject>Cancer Research</subject><subject>Clinical outcomes</subject><subject>Comparative studies</subject><subject>Gastric cancer</subject><subject>Malignancy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Ovarian cancer</subject><subject>Ovarian carcinoma</subject><subject>Surgical Oncology</subject><subject>Tumors</subject><issn>1341-9625</issn><issn>1437-7772</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kc2KFTEQhYMozo--gAsJuHHTmr9OOku5jI4w4EbXITddaXroJNeke8S38VGtO3dUUHARUqS-c1LJIeQFZ284Y-Zt44wr0zFucSk5dPoROcfCdMYY8RhrqXhntejPyEVrt4xxo3vxlJxJZhXvpTonP3YlHXydW8m0RLqUPHUr1ERLDmUp0xxo2dZQEjS6h_UbQKYJVt9Wvx57d6j1mQZfw5xL8rTUeZozNvNEYy2JTsjWMucVGh76BYnJ50Z9Hqkf73wOMNK0HeVb-9fwGXkS_dLg-cN-Sb68v_q8u-5uPn34uHt30wWl-NoFydk-sNCPujfBCBG5BRONNhEEjwJ8r0IYRmv93kaBf9JD0DyCUVwpaeUleX3yPdTydcNZXZpbgGXxGXAwJwQTehBSDoi--gu9LVvFp91T3PZaDAopcaJCLa1ViO5Q5-Trd8eZO-bnTvk5VLj7_JxG0csH622fYPwt-RUYAvIENGzlCeqfu_9j-xPVeqon</recordid><startdate>20190801</startdate><enddate>20190801</enddate><creator>Kajiyama, Hiroaki</creator><creator>Suzuki, Shiro</creator><creator>Utsumi, Fumi</creator><creator>Yoshikawa, Nobuhisa</creator><creator>Nishino, Kimihiro</creator><creator>Ikeda, Yoshiki</creator><creator>Niimi, Kaoru</creator><creator>Yamamoto, Eiko</creator><creator>Kawai, Michiyasu</creator><creator>Shibata, Kiyosumi</creator><creator>Nagasaka, Tetsuro</creator><creator>Kikkawa, Fumitaka</creator><general>Springer Singapore</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0493-1825</orcidid></search><sort><creationdate>20190801</creationdate><title>Comparison of long-term oncologic outcomes between metastatic ovarian carcinoma originating from gastrointestinal organs and advanced mucinous ovarian carcinoma</title><author>Kajiyama, Hiroaki ; Suzuki, Shiro ; Utsumi, Fumi ; Yoshikawa, Nobuhisa ; Nishino, Kimihiro ; Ikeda, Yoshiki ; Niimi, Kaoru ; Yamamoto, Eiko ; Kawai, Michiyasu ; Shibata, Kiyosumi ; Nagasaka, Tetsuro ; Kikkawa, Fumitaka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-c310bc0c5d657c722f19e7f767fe21f2ea54cc8d99ab9f26255ec61fe74144393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Cancer Research</topic><topic>Clinical outcomes</topic><topic>Comparative studies</topic><topic>Gastric cancer</topic><topic>Malignancy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Ovarian cancer</topic><topic>Ovarian carcinoma</topic><topic>Surgical Oncology</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kajiyama, Hiroaki</creatorcontrib><creatorcontrib>Suzuki, Shiro</creatorcontrib><creatorcontrib>Utsumi, Fumi</creatorcontrib><creatorcontrib>Yoshikawa, Nobuhisa</creatorcontrib><creatorcontrib>Nishino, Kimihiro</creatorcontrib><creatorcontrib>Ikeda, Yoshiki</creatorcontrib><creatorcontrib>Niimi, Kaoru</creatorcontrib><creatorcontrib>Yamamoto, Eiko</creatorcontrib><creatorcontrib>Kawai, Michiyasu</creatorcontrib><creatorcontrib>Shibata, Kiyosumi</creatorcontrib><creatorcontrib>Nagasaka, Tetsuro</creatorcontrib><creatorcontrib>Kikkawa, Fumitaka</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kajiyama, Hiroaki</au><au>Suzuki, Shiro</au><au>Utsumi, Fumi</au><au>Yoshikawa, Nobuhisa</au><au>Nishino, Kimihiro</au><au>Ikeda, Yoshiki</au><au>Niimi, Kaoru</au><au>Yamamoto, Eiko</au><au>Kawai, Michiyasu</au><au>Shibata, Kiyosumi</au><au>Nagasaka, Tetsuro</au><au>Kikkawa, Fumitaka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of long-term oncologic outcomes between metastatic ovarian carcinoma originating from gastrointestinal organs and advanced mucinous ovarian carcinoma</atitle><jtitle>International journal of clinical oncology</jtitle><stitle>Int J Clin Oncol</stitle><addtitle>Int J Clin Oncol</addtitle><date>2019-08-01</date><risdate>2019</risdate><volume>24</volume><issue>8</issue><spage>950</spage><epage>956</epage><pages>950-956</pages><issn>1341-9625</issn><eissn>1437-7772</eissn><abstract>Background
Occasionally, ovarian tumors are found to have originated from non-ovarian organs as metastatic lesions since the ovary is a common site of metastasis from many cancers. The aim of the current study was to estimate the long-term oncologic outcome of patients with metastatic mucinous ovarian carcinoma (MmOC) in comparison with those with primary mucinous ovarian carcinoma (PmOC) at an advanced stage.
Materials and methods
The data of one hundred and sixty-seven patients with mucinous ovarian cancer, including 91 patients with MmOC from the digestive organs and 76 patients with stage III–IV PmOC, were retrospectively analyzed. The prognostic significances of clinicopathologic factors were evaluated employing both uni- and multivariable analyses. Pathological slides were evaluated based on centralized pathological review.
Results
The median age of patients with PmOC and MmOC was 55 (18–81) and 51 years (30–82), respectively. With follow-up of a total of 167 patients, 145 patients (86.8%) developed recurrence. In addition, 122 patients (73.0%) died of the disease. Regardless of the residual tumor status, patients with PmOC did not a show a significantly poorer OS than those with MmOC. Furthermore, in a Cox multivariable hazard model, after adjustment for various clinicopathologic confounders, a gastric cancer (GC)-originated tumor and larger residual tumor were significant predictors of poorer OS [GC (vs. PmOC): HR (95% CI) 2.205 (1.303–3.654),
P
= 0.0036].
Conclusion
The oncologic outcome of patients with MmOC was extremely poor; however, it was almost the same as that of those with PmOC. We should recognize MmOC derived from gastric carcinoma as a highly aggressive malignancy.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>30941534</pmid><doi>10.1007/s10147-019-01438-6</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-0493-1825</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1341-9625 |
| ispartof | International journal of clinical oncology, 2019-08, Vol.24 (8), p.950-956 |
| issn | 1341-9625 1437-7772 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2202682338 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Cancer Research Clinical outcomes Comparative studies Gastric cancer Malignancy Medicine Medicine & Public Health Metastases Metastasis Oncology Original Article Ovarian cancer Ovarian carcinoma Surgical Oncology Tumors |
| title | Comparison of long-term oncologic outcomes between metastatic ovarian carcinoma originating from gastrointestinal organs and advanced mucinous ovarian carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T06%3A13%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20long-term%20oncologic%20outcomes%20between%20metastatic%20ovarian%20carcinoma%20originating%20from%20gastrointestinal%20organs%20and%20advanced%20mucinous%20ovarian%20carcinoma&rft.jtitle=International%20journal%20of%20clinical%20oncology&rft.au=Kajiyama,%20Hiroaki&rft.date=2019-08-01&rft.volume=24&rft.issue=8&rft.spage=950&rft.epage=956&rft.pages=950-956&rft.issn=1341-9625&rft.eissn=1437-7772&rft_id=info:doi/10.1007/s10147-019-01438-6&rft_dat=%3Cproquest_cross%3E2201956284%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2201956284&rft_id=info:pmid/30941534&rfr_iscdi=true |